News

News

Date Title and Summary Additional Formats
Toggle Summary "Non-systemic drugs: a critical review" published in Current Pharmaceutical Design
"Non-systemic drugs: a critical review" published in Current Pharmaceutical Design
View HTML
Toggle Summary Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada
License Agreement Advances First-in-Class Tenapanor for IBS-C and Hyperphosphatemia in Canada Ardelyx to Receive Up to CAD 25 Million in Upfront Payment and Subsequent Milestones FREMONT, Calif. , March 19, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced a license agreement with
View HTML
Toggle Summary Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
Ardelyx to Receive a $30 Million Upfront Payment and Subsequent Milestones FREMONT, Calif. and TOKYO , Nov. 28, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) and Kyowa Hakko Kirin Co., Ltd. ( Tokyo : 4151, " Kyowa Hakko Kirin "), today announced that they have entered into a license agreement
View HTML
Toggle Summary Ardelyx Announces Closing of Public Offering Including Exercise of Underwriters' Right to Purchase Additional Shares
FREMONT, Calif. , Jan. 13, 2016 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the completion of its previously announced underwritten public offering of 8,625,000 shares of its common
View HTML
Toggle Summary Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call
FREMONT, Calif. , Aug. 1, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that it plans to report its second quarter 2018 financial results after market close on Tuesday, August 7, 2018 . Management will host a conference call and webcast that afternoon at 4:30 p.m.
View HTML
Toggle Summary Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference
FREMONT, Calif. , Aug. 2, 2017 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, today announced that management will host a conference call in conjunction with its second
View HTML
Toggle Summary Ardelyx Announces Departure of Chief Scientific Officer
FREMONT, Calif. , Feb. 12, 2018 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX) today announced that Jeremy Caldwell , Ph.D., chief scientific officer, will be leaving the company, effective February 16, 2018 , to pursue a position as chief executive officer of an early stage biotech start-up company
View HTML
Toggle Summary Ardelyx Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
FREMONT, Calif. , June 24, 2014 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced the closing of its initial public offering of 4,928,900 shares of common stock at an initial public offering
View HTML
Toggle Summary Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia
FREMONT, Calif. , Jan. 3, 2017 /PRNewswire/ -- Ardelyx, Inc. ( NASDAQ : ARDX), a clinical-stage company focused on enhancing the treatment of patients with gastrointestinal and cardiorenal diseases, today announced the initiation of a Phase 3 clinical trial and an onset-of-action clinical trial
View HTML
Toggle Summary Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China
Ardelyx to Receive Up to $125 Million in Upfront Payment and Subsequent Milestones FREMONT, Calif. , Dec. 11, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that the company has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company
View HTML